GlassScriptPhysician profile
Eugene S Park
NPI 1275654782
$2,477.16
in general payments reported to CMS, 2019-2025
15 companies · $73.13 in 2025
The $73.13 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.19 · 2021: $28.89 · 2022: $1,895 · 2023: $192 · 2024: $233 · 2025: $73.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.39 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,069.15 | 2022 | |
| Boston Scientific Corporation | $932.40 | 2022-2024 | Ams 700 |
| Olympus America INC. | $128.06 | 2022-2024 | Bovie |
| Endo Pharmaceuticals INC. | $69.88 | 2021-2023 | Aveed, Xiaflex |
| Edap Technomed INC | $66.00 | 2024 | |
| Astellas Pharma US INC | $45.90 | 2019-2024 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| C. R. Bard, INC. & Subsidiaries | $20.38 | 2025 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Medtronic, INC. | $18.92 | 2022 | |
| Sumitomo Pharma America, INC. | $18.60 | 2024 | Orgovyx |
| Antares Pharma, INC. | $17.69 | 2025 | Xyosted |
| Palette Life Sciences, INC. | $16.57 | 2022 | |
| 180 Medical, INC. | $15.61 | 2019 | |
| Urogen Pharma, INC. | $12.01 | 2021 | |
| Amgen INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.